Register for our free email digests:
Latest From TR-Pharm
After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.
Many local pharma companies in Turkey have been launching capital investments in new production facilities for biologics and biosimilars in the hope of attracting new foreign partners and have already met with some success, but a number of obstacles remain.
The Turkish market for biotech drugs and biologics is growing strongly but most are imported and the country is now determined to develop its infrastructure for local manufacturing through a series of moves. While there has been some progress, it is not yet certain if this is enough to meet high official expectations and convince investors.
More Indian firms appear keen to target the Turkish market for biosimilars. After Dr Reddy's outlined its plans earlier this year, Zydus Cadila has now firmed up an alliance with Turkey's Eczacibasi Ilac Pazarlama AS for biosimilars especially in the oncology segment.
- Large Molecule
- Therapeutic Areas
- Middle East
- Parent & Subsidiaries
- Senior Management
Ismet Ince, Dir., Fin. & Bus. Dev.
Orkun Eray, PhD, Medical Dir.
- Contact Info
Phone: 212 386 31 30
Esentepe Mahallesi, Büyükdere Caddesi
Istanbul, 14 34394
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.